-
1.发明公开CANCER DIAGNOSIS AND TREATMENT USING ANTI-ROBO1 ANTIBODY 有权KREBSDIAGNOSE UND BEHANDLUNG UNTER VERWENDUNG EINES ANTI-ROBO1-ANTIKÖRPERS
公开(公告)号：EP1744162A4
公开(公告)日：2007-07-11
申请号：EP05728904
申请日：2005-03-31
发明人： ABURATANI HIROYUKI , HIPPO YOSHITAKA , WATANABE AKIRA , FUKAYAMA MASASHI , ITO YUKIO , ARAI MASAHIRO , ITO HIROTAKA , OHTOMO TOSHIHIKO , FUNAHASHI SHIN-ICHI , KINOSHITA YASUKO
IPC分类号： G01N33/574 , C07K16/30 , C12N15/02 , C12N15/09 , G01N33/576
CPC分类号： C07K16/2803 , A61K2039/505 , C07K16/30 , C07K16/303 , C07K2317/73 , C07K2317/732 , C07K2317/734 , G01N33/57438 , G01N33/57488 , G01N33/576
摘要： A method of cancer diagnosis characterized in that ROBO1 protein is detected. Further, there is disclosed a method of treating diseases attributed to abnormal cell growth, comprising administering an antibody capable of binding to ROBO1, and are disclosed, comprising an antibody capable of binding to ROBO1 as an active ingredient, a pharmaceutical composition, cytostatic agent and anticancer agent. Still further, there is disclosed a method of inhibiting the growth of ROBO1 expression cells or method of inducing cytotoxicity in ROBO1 expression cells, comprising bringing an antibody capable of binding to ROBO1 into contact with ROBO1 expression cells. Moreover, there is disclosed a method of monitoring the intensification of hepatitis severity, comprising detection of ROBO1 protein.
摘要翻译： 公开了一种诊断癌症的方法，包括检测ROBO1蛋白。 此外，用于治疗由异常细胞生长引起的疾病的方法包括施用与ROBO1结合的抗体，以及药物组合物，细胞生长抑制剂和抗癌剂，其包含结合ROBO1作为有效成分的抗体的方法， 披露。 此外，公开了通过使ROBO1表达细胞与与ROBO1结合的抗体接触来抑制ROBO1表达细胞中的细胞损伤的方法和抑制ROBO1表达细胞的生长的方法。 此外，公开了通过检测ROB01蛋白来监测肝炎进展的方法。
-
公开(公告)号：EP1652923A4
公开(公告)日：2006-07-26
申请号：EP04771625
申请日：2004-08-06
发明人： ABURATANI HIROYUKI , HIPPO YOSHITAKA , TANIGUCHI HIROKAZU , CHEN YONG XIN , ISHIKAWA SHUMPEI , FUKUMOTO SHIN-ICHI , SHIMAMURA TAKAHIRO , KAMIMURA NAOKO , GUO YING QIU , YAMAMOTO SHOGO , ITO YUKIO , ITO HIROTAKA , OHTOMO TOSHIHIKO
IPC分类号： C12N15/12 , A61K31/711 , A61K38/00 , A61K39/00 , C07K14/82 , C07K16/30 , C07K16/32 , C12N5/10 , C12Q1/68 , G01N33/15 , G01N33/50 , G01N33/574
CPC分类号： C12Q1/6886 , A61K31/711 , A61K38/00 , A61K39/0011 , C07K14/82 , C07K16/30 , C12Q2600/136 , G01N33/57484
摘要： A protein encoded by a gene having a nucleotide sequence represented by any of SEQ ID NOS:1 to 65 or its fragment; an antibody recognizing the same or an antigen-binding fragment thereof; and a polynucleotide having a nucleotide sequence comprising at least 12 consecutive nucleotides in any of the nucleotide sequences represented by SEQ ID NOS:1 to 65 or a nucleotide sequence complementary thereto: The above gene and protein are useful as diagnostics and remedies for cancer.
摘要翻译： 由具有序列号1〜65中任一项所示的碱基序列的基因或其片段编码的蛋白质; 识别相同抗体的抗体或其抗原结合片段; 以及具有在序列号1〜65所示的碱基序列中的任一个碱基序列中具有至少12个连续碱基的碱基序列或与其互补的碱基序列的多核苷酸。上述基因和蛋白质作为癌的诊断和治疗是有用的。
-
公开(公告)号：EP1327681A4
公开(公告)日：2004-09-01
申请号：EP01978852
申请日：2001-10-22
发明人： FUKUSHIMA NAOSHI , TSUCHIYA MASAYUKI , UNO SHINSUKE , OHTOMO TOSHIHIKO , YABUTA NAOHIRO , TSUNODA HIROYUKI
CPC分类号： C07K16/3061 , A61K38/00 , A61K2039/505 , C07K16/24 , C07K16/28 , C07K16/2866 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/56 , C07K2317/622 , C07K2317/73 , C07K2319/00
摘要： A modified antibody containing at least two H chain V domains and at least two L chain V domains of a monoclonal antibody which transduces a signal into cells by crosslinking a cell surface molecule to thereby serve as an agonist. Because of being usable as a signal transduction agonist, this modified antibody is useful as a preventive and/or a remedy etc. for various diseases such as caner, inflammation, dysendocrinism and blood diseases.
-
公开(公告)号：EP1081224A4
公开(公告)日：2003-07-02
申请号：EP99918302
申请日：1999-04-30
CPC分类号： C12N15/1051 , C07K14/705 , C07K16/00 , C07K16/2866 , C07K2317/24 , C07K2317/622 , C07K2319/00 , C12N15/1034
摘要： A method for isolating a gene encoding a membrane-bound protein characterized by fusing a functional protein with a fused protein per se, differing from the existing TMT method wherein an epitope recognized by an antibody is carried in a fused protein. This method makes it possible to selectively isolate a gene encoding a membrane-bound protein.
-
公开(公告)号：EP1710308A4
公开(公告)日：2008-11-19
申请号：EP04820305
申请日：2004-12-10
CPC分类号： C07K16/00 , C07K16/18 , C07K2317/622 , C07K2317/75
摘要： Antihuman Mpl antibody is obtained and purified. By using a genetic engineering technique, a single chain antibody of the antihuman Mpl antibody is further constructed. This antibody shows a high agonistic activity. This fact indicates that the activity of an antibody can be reinforced by binding two or more heavy chain variable domains to two or more light chain variable domains with the use of a linker to give a single chain polypeptide.
-
公开(公告)号：EP1043586A4
公开(公告)日：2004-07-28
申请号：EP98950354
申请日：1998-10-22
CPC分类号： G01N33/68 , G01N2333/495
摘要： A method of screening substances which inhibit the bonding of TAK1 polypeptide to TAB1 polypeptide, characterized by contacting TAK1 polypeptide and a sample with TAB1 polypeptide and detecting or determining the TAK1 polypeptide bonded to the TAB1 polypeptide.
-
公开(公告)号：EP1491631A4
公开(公告)日：2005-07-20
申请号：EP03715597
申请日：2003-03-28
IPC分类号： A61K38/00 , C07K14/705 , C12N7/00 , C12N15/12 , C12N15/866 , G01N33/569 , C12Q1/70 , G01N33/15 , G01N33/50
CPC分类号： C12N15/86 , A61K38/00 , C07K14/705 , C12N7/00 , C12N2710/14121 , C12N2710/14143 , G01N2333/01 , G01N2500/10
摘要： It is considered that a method of measuring a transporter activity by using a budding vaculovirus expressing no endogenous transporter on its membrane has a low background and thus enables highly sensitive measurement of the target activity. Using this method, functional changes caused by SNPs in transporters can be measured on substrates over a broader scope. Thus, it is applicable to tailor made therapy programs.
-
公开(公告)号：EP1260584A4
公开(公告)日：2004-05-19
申请号：EP01904475
申请日：2001-02-15
IPC分类号： C07K14/47 , C07K14/705 , C12N15/12
CPC分类号： C07K14/705 , C07K14/47 , C07K2319/02
摘要： A DNA encoding a novel protein SMAP-1, which has a signal sequence, is successfully isolated by screening a cDNA library originating in human fetal hepatocytes with the use of an originally developed TMT method. The expression characteristics and structural characteristics of SMAP-1 suggest that it is a molecule having an important role in vivo .
-
9.发明公开
公开(公告)号：EP3141603A4
公开(公告)日：2017-12-27
申请号：EP15789676
申请日：2015-05-08
发明人： OHTOMO TOSHIHIKO , TANAKA TAKAYOSHI , SUGITANI YASUO , PUIG OSCAR , CHEN GONG , LEE RUEY-MIN , BELOUSOV ANTON , CHEN YA-CHI , REIS BERNHARD
CPC分类号： C07K16/303 , A61K47/486 , A61K47/6859 , A61K2039/505 , A61K2039/55 , C07K2317/24 , C07K2317/732 , C07K2317/92 , C12N15/09 , C12Q1/02 , C12Q1/6886 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158 , G01N33/5011 , G01N33/56972 , G01N33/57438 , G01N2800/52 , G01N2800/7028
摘要： The present invention discloses a method for determining the efficacy of GPC3-targeting drug therapy for cancer in a patient before the start of GPC3-targeting drug therapy or a patient or determining the continuation of GPC3-targeting drug therapy for a patient, including measuring the number of an immunocyte or an expression level of a molecule expressed on the immunocyte in a biological sample isolated from the patient before the start of GPC3-targeting drug therapy and/or the patient treated with the GPC3-targeting drug therapy, wherein when the number of an immunocyte or an expression level of a molecule expressed on the immunocyte is a predetermined value, the efficacy of the GPC3-targeting drug therapy is determined or the continuation of the GPC3-targeting drug therapy is determined. The present invention also discloses a GPC3-targeting drug or a preparation which is to be administered to a patient for which the efficacy of the GPC3-targeting drug therapy has been determined or the continuation of the GPC3-targeting drug therapy has been determined.
-
公开(公告)号：EP0960936A4
公开(公告)日：2005-01-19
申请号：EP97942246
申请日：1997-10-03
发明人： ONO KOICHIRO , OHTOMO TOSHIHIKO , TSUCHIYA MASAYUKI , YOSHIMURA YASUSHI , KOISHIHARA YASUO , KOSAKA MASAAKI
IPC分类号： C07K16/42 , A61K38/00 , A61K39/395 , C07K16/28 , C07K16/30 , C12N1/15 , C12N1/19 , C12N1/21 , C12N15/13 , C12N15/63 , C12P21/08
CPC分类号： C07K16/2896 , A61K38/00 , C07K16/3061 , C07K2317/24 , C07K2317/732 , C07K2317/734 , C07K2319/00
摘要： A reconstituted human anti-HM1.24 antibody comprising: (A) an L chain comprising: (1) a human L chain C region and (2) an L chain V region containing a human L chain FR and an L chain CDR of a mouse anti-HM1.24 monoclonal antibody; and (B) an H chain comprising: (1) a human H chain C region and (2) an H chain V region containing a human H chain FR and an H chain CDR of a mouse anti-HM1.24 monoclonal antibody. Because of mostly originating in the human antibody and the CDR being less antigenic, this reconstituted human antibody has a low antigenicity against man and, therefore, can be expected as therapeutically usable.
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.012 秒)
